IMPACT OF CD4 T CELL COUNT ON THE OUTCOME OF PLANNED TREATMENT INTERRUPTIONS IN EARLY-TREATED HUMAN IMMUNODEFICIENCY VIRUS-INFECTED CHILDREN

Early highly active antiretroviral therapy is recommended in all vertically human immunodeficiency virus (HIV)-infected infants. We describe the long-term immunologic outcome after planned treatment interruption (PTI) in 7 children diagnosed and treated during acute HIV infection (age < 12 weeks)...

ver descrição completa

Detalhes bibliográficos
Autores: Fortuny C, Noguera-Julian A, Alsina L, Bellido R, Sánchez E, Muñoz-Almagro C, Ruiz L, Jiménez R
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2011
País:España
Recursos:Fundació Sant Joan de Déu
Repositorio:r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
OAI Identifier:oai:fsjd.fundanetsuite.com:p1038
Acesso em linha:https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=1038
Access Level:acceso abierto
Palavra-chave:acute HIV infection
vertically transmitted HIV infection
highly active antiretroviral therapy
immunologic evolution
treatment interruption
id ES_bb329fae799a8010d63d7d5c04e1f49d
oai_identifier_str oai:fsjd.fundanetsuite.com:p1038
network_acronym_str ES
network_name_str España
repository_id_str
spelling IMPACT OF CD4 T CELL COUNT ON THE OUTCOME OF PLANNED TREATMENT INTERRUPTIONS IN EARLY-TREATED HUMAN IMMUNODEFICIENCY VIRUS-INFECTED CHILDRENFortuny CNoguera-Julian AAlsina LBellido RSánchez EMuñoz-Almagro CRuiz LJiménez Racute HIV infectionvertically transmitted HIV infectionhighly active antiretroviral therapyimmunologic evolutiontreatment interruptionEarly highly active antiretroviral therapy is recommended in all vertically human immunodeficiency virus (HIV)-infected infants. We describe the long-term immunologic outcome after planned treatment interruption (PTI) in 7 children diagnosed and treated during acute HIV infection (age < 12 weeks). Children had remained a median of 57 months off treatment, 3 of them indefinitely. The 2 patients with the lowest nadir CD4% reinitiated highly active antiretroviral therapy because of a CD4 cell decline of < 20%; 2 children resumed treatment because of clinical progression and parents' wishes. All patients experienced a decrease in CD4% after PTI, which particularly affected the naive subpopulation. The interferon-gamma response against HIV-p24 antigen directly correlated with nadir CD4%. Our results suggest that early treatment in HIV-infected infants increases their potential to safely control viral replication after PTI for long periods.LIPPINCOTT WILLIAMS & WILKINS2011info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=1038PEDIATRIC INFECTIOUS DISEASE JOURNALISSN: 08913668ISSNe: 15320987reponame:r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déuinstname:Fundació Sant Joan de DéuInglésinfo:eu-repo/semantics/openAccessoai:fsjd.fundanetsuite.com:p10382026-05-27T12:37:41Z
dc.title.none.fl_str_mv IMPACT OF CD4 T CELL COUNT ON THE OUTCOME OF PLANNED TREATMENT INTERRUPTIONS IN EARLY-TREATED HUMAN IMMUNODEFICIENCY VIRUS-INFECTED CHILDREN
title IMPACT OF CD4 T CELL COUNT ON THE OUTCOME OF PLANNED TREATMENT INTERRUPTIONS IN EARLY-TREATED HUMAN IMMUNODEFICIENCY VIRUS-INFECTED CHILDREN
spellingShingle IMPACT OF CD4 T CELL COUNT ON THE OUTCOME OF PLANNED TREATMENT INTERRUPTIONS IN EARLY-TREATED HUMAN IMMUNODEFICIENCY VIRUS-INFECTED CHILDREN
Fortuny C
acute HIV infection
vertically transmitted HIV infection
highly active antiretroviral therapy
immunologic evolution
treatment interruption
title_short IMPACT OF CD4 T CELL COUNT ON THE OUTCOME OF PLANNED TREATMENT INTERRUPTIONS IN EARLY-TREATED HUMAN IMMUNODEFICIENCY VIRUS-INFECTED CHILDREN
title_full IMPACT OF CD4 T CELL COUNT ON THE OUTCOME OF PLANNED TREATMENT INTERRUPTIONS IN EARLY-TREATED HUMAN IMMUNODEFICIENCY VIRUS-INFECTED CHILDREN
title_fullStr IMPACT OF CD4 T CELL COUNT ON THE OUTCOME OF PLANNED TREATMENT INTERRUPTIONS IN EARLY-TREATED HUMAN IMMUNODEFICIENCY VIRUS-INFECTED CHILDREN
title_full_unstemmed IMPACT OF CD4 T CELL COUNT ON THE OUTCOME OF PLANNED TREATMENT INTERRUPTIONS IN EARLY-TREATED HUMAN IMMUNODEFICIENCY VIRUS-INFECTED CHILDREN
title_sort IMPACT OF CD4 T CELL COUNT ON THE OUTCOME OF PLANNED TREATMENT INTERRUPTIONS IN EARLY-TREATED HUMAN IMMUNODEFICIENCY VIRUS-INFECTED CHILDREN
dc.creator.none.fl_str_mv Fortuny C
Noguera-Julian A
Alsina L
Bellido R
Sánchez E
Muñoz-Almagro C
Ruiz L
Jiménez R
author Fortuny C
author_facet Fortuny C
Noguera-Julian A
Alsina L
Bellido R
Sánchez E
Muñoz-Almagro C
Ruiz L
Jiménez R
author_role author
author2 Noguera-Julian A
Alsina L
Bellido R
Sánchez E
Muñoz-Almagro C
Ruiz L
Jiménez R
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv acute HIV infection
vertically transmitted HIV infection
highly active antiretroviral therapy
immunologic evolution
treatment interruption
topic acute HIV infection
vertically transmitted HIV infection
highly active antiretroviral therapy
immunologic evolution
treatment interruption
description Early highly active antiretroviral therapy is recommended in all vertically human immunodeficiency virus (HIV)-infected infants. We describe the long-term immunologic outcome after planned treatment interruption (PTI) in 7 children diagnosed and treated during acute HIV infection (age < 12 weeks). Children had remained a median of 57 months off treatment, 3 of them indefinitely. The 2 patients with the lowest nadir CD4% reinitiated highly active antiretroviral therapy because of a CD4 cell decline of < 20%; 2 children resumed treatment because of clinical progression and parents' wishes. All patients experienced a decrease in CD4% after PTI, which particularly affected the naive subpopulation. The interferon-gamma response against HIV-p24 antigen directly correlated with nadir CD4%. Our results suggest that early treatment in HIV-infected infants increases their potential to safely control viral replication after PTI for long periods.
publishDate 2011
dc.date.none.fl_str_mv 2011
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=1038
url https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=1038
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv LIPPINCOTT WILLIAMS & WILKINS
publisher.none.fl_str_mv LIPPINCOTT WILLIAMS & WILKINS
dc.source.none.fl_str_mv PEDIATRIC INFECTIOUS DISEASE JOURNAL
ISSN: 08913668
ISSNe: 15320987
reponame:r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname:Fundació Sant Joan de Déu
instname_str Fundació Sant Joan de Déu
reponame_str r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
collection r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869418004261896192
score 15,812429

Registos relacionados